223 related articles for article (PubMed ID: 32926247)
21. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
[TBL] [Abstract][Full Text] [Related]
22. Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis.
Navarro-Compán V; Baraliakos X; Magrey M; Östör A; Saffore CD; Mittal M; Song IH; Ganz F; Stigler J; Deodhar A
Rheumatol Ther; 2023 Jun; 10(3):679-691. PubMed ID: 36820984
[TBL] [Abstract][Full Text] [Related]
23. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
[TBL] [Abstract][Full Text] [Related]
24. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.
van der Heijde DM; Revicki DA; Gooch KL; Wong RL; Kupper H; Harnam N; Thompson C; Sieper J;
Arthritis Res Ther; 2009; 11(4):R124. PubMed ID: 19686597
[TBL] [Abstract][Full Text] [Related]
25. Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials.
Ho A; Younis I; Le QA
Semin Arthritis Rheum; 2022 Jun; 54():151996. PubMed ID: 35339841
[TBL] [Abstract][Full Text] [Related]
26. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.
Dubreuil M; Navarro-Compán V; Boonen A; Gaffney K; Gensler LS; de la Loge C; Vaux T; Fleurinck C; Massow U; Taieb V; Mørup MF; Deodhar A; Rudwaleit M
RMD Open; 2024 Jun; 10(2):. PubMed ID: 38834351
[TBL] [Abstract][Full Text] [Related]
27. Relationships of Work Productivity and Activity Impairment With Patient-Reported Outcomes in Ankylosing Spondylitis: Results From Two Trials.
Magrey M; Wei JC; Yndestad A; Bushmakin AG; Cappelleri JC; Dina O; Deodhar A
Arthritis Care Res (Hoboken); 2024 Mar; 76(3):359-365. PubMed ID: 37909386
[TBL] [Abstract][Full Text] [Related]
28. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
Deodhar A; Braun J; Inman RD; van der Heijde D; Zhou Y; Xu S; Han C; Hsu B
Ann Rheum Dis; 2015 Apr; 74(4):757-61. PubMed ID: 25387477
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A
Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685
[TBL] [Abstract][Full Text] [Related]
30. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.
Braun J; Deodhar A; Inman RD; van der Heijde D; Mack M; Xu S; Hsu B
Ann Rheum Dis; 2012 May; 71(5):661-7. PubMed ID: 22012970
[TBL] [Abstract][Full Text] [Related]
31. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
32. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
[TBL] [Abstract][Full Text] [Related]
33. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study.
Braun J; Baraliakos X; Hermann KG; van der Heijde D; Inman RD; Deodhar AA; Baratelle A; Xu S; Xu W; Hsu B
Ann Rheum Dis; 2012 Jun; 71(6):878-84. PubMed ID: 22128083
[TBL] [Abstract][Full Text] [Related]
34. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial.
Deodhar A; Braun J; Inman RD; Mack M; Parasuraman S; Buchanan J; Hsu B; Gathany T; van der Heijde D
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1266-71. PubMed ID: 20506403
[TBL] [Abstract][Full Text] [Related]
35. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE).
van der Heijde D; Braun J; Deodhar A; Inman RD; Xu S; Mack ME; Hsu B
Rheumatology (Oxford); 2013 Feb; 52(2):321-5. PubMed ID: 23024015
[TBL] [Abstract][Full Text] [Related]
36. [The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis].
Ma H; Sun F; Zhang YM; Zhang H; Zhu J; Deng XH; Zhang JL; Huang F
Zhonghua Nei Ke Za Zhi; 2017 Dec; 56(12):935-939. PubMed ID: 29202535
[No Abstract] [Full Text] [Related]
37. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
38. Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study.
van der Heijde D; Deodhar A; Inman RD; Braun J; Hsu B; Mack M
Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1919-22. PubMed ID: 22740380
[TBL] [Abstract][Full Text] [Related]
39. Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease.
Peyrin-Biroulet L; Louis E; Loftus EV; Lacerda A; Zhou Q; Sanchez Gonzalez Y; Ghosh S
Adv Ther; 2021 May; 38(5):2339-2352. PubMed ID: 33755884
[TBL] [Abstract][Full Text] [Related]
40. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
Maksymowych WP; Gooch KL; Wong RL; Kupper H; van der Heijde D
J Rheumatol; 2010 Feb; 37(2):385-92. PubMed ID: 19955052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
